Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma
First patient achieves complete response with new ovarian cancer drug YL205
This is a single-patient case report of a 40-year-old woman with platinum-resistant, BRCA-wildtype high-grade serous ovarian carcinoma treat…
A single patient with advanced ovarian cancer achieved a complete response after 24 weeks of treatment with YL205, a new antibody-drug conju…
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Review of case report suggests multimodal therapy potential for unresectable intraductal papillary mucinous neoplasms of the bile duct
At-a-Glance
This review of a case report describes two patients with unresectable intraductal papillary mucinous neoplasms of the bile duct treated with…
A new three-drug combination shrank a rare bile duct tumor in one patient and stopped another from growing, offering hope for a cancer with …
Systematic review and meta-analysis compares intravesical gemcitabine/docetaxel versus BCG for non-muscle-invasive bladder cancer
Gemcitabine and docetaxel show similar recurrence-free survival to BCG for bladder cancer
This systematic review and meta-analysis evaluated intravesical gemcitabine and docetaxel compared with Bacillus Calmette-Guérin (BCG) in pa…
A meta-analysis of 1634 patients found gemcitabine and docetaxel offered recurrence-free survival rates comparable to BCG therapy for non-mu…
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
New analysis shows pucotenlimab improves outcomes for several solid tumor types
This meta-analysis evaluated pucotenlimab (HX008) in patients with gastric, gastroesophageal junction, triple-negative breast cancer, melano…
A new analysis of pucotenlimab shows significantly improved outcomes versus control for patients with gastric cancer, triple-negative breast…
Case report and literature review of ENKTL presenting with ocular symptoms and treated with GemOx
A Rare Eye Symptom Led Doctors Down the Wrong Path for Months
This case report and literature review describes a single patient with extranodal natural killer/T cell lymphoma presenting with ocular symp…
Double vision and sinus scans that looked clean hid a rare lymphoma that stole a man's sight after months of wrong treatments.
Durvalumab plus chemotherapy improves event-free and overall survival in muscle-invasive bladder cancer compared to chemotherapy alone
New treatment approach improves survival for advanced bladder cancer patients before surgery
This randomized, phase III, open-label trial evaluated neoadjuvant and adjuvant durvalumab combined with gemcitabine and cisplatin versus ge…
Adding an immune drug to standard chemotherapy before bladder surgery helps patients stay cancer-free longer and live longer than older trea…
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in Chinese adults with advanced biliary tract carcinoma
Could adding pembrolizumab help Chinese adults live longer with advanced biliary tract carcinoma?
This phase 3 randomized controlled trial enrolled 158 Chinese adults with advanced or unresectable biliary tract carcinoma.
A completed study in China compared adding pembrolizumab to chemotherapy for advanced bile duct cancer, tracking how long 158 adults survive…
Gemcitabine exposure associated with higher TP53 and PI3K pathway alterations in pancreatic ductal adenocarcinoma tumors
AI Finds Hidden Keys to Pancreatic Cancer Survival
This cohort study analyzed 184 pancreatic ductal adenocarcinoma tumors to assess the association between gemcitabine exposure and molecular …
Age and gemcitabine exposure drive distinct genetic patterns in pancreatic cancer, directly influencing survival rates for patients with key…
Camonsertib plus gemcitabine shows preliminary activity in advanced solid tumors with DDR alterations
New Drug Combo Helps Some Solid Tumors Grow Slower
This Phase Ib trial evaluated camonsertib plus gemcitabine in 76 patients with advanced solid tumors harboring DDR gene alterations.
This combination might offer a new hope for patients whose tumors have stopped responding to standard treatments.
Penpulimab plus chemotherapy significantly improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma
New drug plus chemo delays cancer growth in advanced nasopharyngeal cases
This randomized, double-blind phase 3 trial evaluated penpulimab combined with cisplatin/carboplatin and gemcitabine versus placebo plus che…
Adding penpulimab to chemotherapy delays cancer growth by nearly three months in advanced nasopharyngeal cases, offering new hope for patien…